A5088439837- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Cancer Cells and Metastasis
- Epigenetics and DNA Methylation
- Pancreatic and Hepatic Oncology Research
- 3D Printing in Biomedical Research
- Genetic factors in colorectal cancer
- Microfluidic and Bio-sensing Technologies
- Pharmacogenetics and Drug Metabolism
- RNA modifications and cancer
- Genomics and Rare Diseases
- Gastric Cancer Management and Outcomes
- Genetic Associations and Epidemiology
- Micro and Nano Robotics
- Ethics in Clinical Research
- Cytokine Signaling Pathways and Interactions
- Ovarian cancer diagnosis and treatment
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Disaster Management and Resilience
- Lung Cancer Research Studies
- Neutropenia and Cancer Infections
- Ferroptosis and cancer prognosis
Hôpital Lyon Sud
2019-2025
Hospices Civils de Lyon
2019-2025
Université Claude Bernard Lyon 1
2019-2025
Centre de Recherche en Cancérologie de Lyon
2019-2025
Laboratoire de Biochimie
2021
Hôpital Edouard Herriot
2021
Cancer Institute (WIA)
2019
Cancer Research Center
2019
Inserm
2019
Centre National de la Recherche Scientifique
2019
The isolation of circulating tumor cells (CTCs) directly from blood, as a liquid biopsy, could lead to paradigm shift in cancer care. MagPure chip provides powerful tool for subsequent purification CTCs and dissection their clinical information.
Non‐small cell lung cancer (NSCLC) affects 10–50% of patients with epidermal growth factor receptor ( EGFR ) mutations. Osimertinib is a third‐generation tyrosine kinase inhibitor (TKI) that radically changes the outcome tumors bearing sensitizing or T790M resistance However, usually occurs, and new therapeutic combinations need to be explored. The chorioallantoic membrane (CAM) xenograft model ideal for studying aggressive tumor responses complex due its vascularization microenvironment....
Posaconazole (PCZ) is recommended for antifungal prophylaxis in neutropenic patients with acute myeloid leukemia (AML). Although the delayed-release (DR) tablet of PCZ has better bioavailability than oral suspension, serum target trough concentrations are not achieved all patients. Because metabolism mainly mediated by uridine diphosphate glucuronosyltransferase 1A4 (UGT1A4), we investigated whether UGT1A4 polymorphisms affect exposure. This single-center prospective cohort study included 88...
Magnetophoresis-based microfluidic devices offer simple and reliable manipulation of micro-scale objects provide a large panel applications, from selective trapping to high-throughput sorting. However, the fabrication integration magnets in microsystems involve complex expensive processes. Here we report on an inexpensive easy-to-handle process micrometer-scale permanent magnets, based self-organization NdFeB particles polymer matrix (polydimethylsiloxane, PDMS). A study inner structure by...
Patient-Derived Xenografts (PDXs) in the Chorioallantoic Membrane (CAM) are a representative model for studying human tumors. Circulating Tumor Cells (CTCs) involved cancer dissemination and treatment resistance mechanisms. To facilitate research deep analysis of these few cells, significant efforts were made to expand them. We evaluated here whether isolation fresh CTCs from patients with metastatic cancers could provide reliable tumor after CAM xenograft. enrolled 35 patients, breast,...
Abstract Cell‐free plasma DNA (cfDNA) and mimicking circulating tumor cells (mCTCs) have demonstrated tremendous potential for molecular diagnosis of cancer been rapidly implemented in specific settings. However, widespread clinical adoption still faces some obstacles. The purpose was to compare the performance a BEAMing (beads, emulsion, amplification, magnetics) assay (OncoBEAM™‐epidermal growth factor receptor [ EGFR ] [Sysmex Inostics]) next‐generation sequencing (NGS; 56G Oncology panel...
Background: Pharmacogenetics (PGx) aims to determine genetic signatures that can be used in clinical settings individualize treatment for each patient, including anti-cancer drugs, anti-psychotics, and painkillers. Taken together, a better understanding of the impacts variants on corresponding protein function or expression permits prediction pharmacological response: responders, non-responders, those with adverse drug reactions (ADRs). Objective: This work provides comparison between...
The use of ultra-sensitive diagnostic tests to detect clinically actionable somatic alterations within the gene encoding epidermal growth factor receptor (EGFR) circulating cell-free DNA is an important first step in determining eligibility patients with non-small cell lung cancer receive tyrosine kinase inhibitors.We present clinical validation (accuracy, sensitivity, and specificity) a highly sensitive OncoBEAMTM EGFR V2 test, which we compare custom next-generation sequencing assay, for...
Introduction: Progressive advanced non-small cell lung cancer (NSCLC) accounts for about 80–85% of all cancers. Approximately 10–50% patients with NSCLC harbor targetable activating mutations, such as in-frame deletions in Exon 19 (Ex19del) EGFR. Currently, NSCLC, testing sensitizing mutations EGFR is mandatory prior to the administration tyrosine kinase inhibitors. Patients and Methods: Plasma was collected from NSCLC. We carried out targeted NGS using Plasma-SeqSensei™ SOLID CANCER IVD kit...
The molecular profiling of circulating tumor DNA (ctDNA) is a helpful tool not only in cancer treatment, but also the early detection relapse. However, clinical interpretation ctDNA negative result remains challenging. characterization nucleosomes (carrying cell-free DNA) and associated epigenetic modifications (playing key role tumorigenesis different cancers) may provide useful information for patient management, by supporting contributive value profiling. Significantly elevated...
Circulating tumor cells (CTCs) derived from the primary are shed into bloodstream or lymphatic system. These rare (1−10 per mL of blood) warrant a poor prognosis and correlated with shorter overall survival in several cancers (e.g., breast, prostate colorectal). Currently, anti-EpCAM-coated magnetic bead-based CTC capturing system is gold standard test approved by U.S. Food Drug Administration (FDA) for enumerating CTCs bloodstream. This based on use beads coated anti-EpCAM markers, which...
Circulating tumor cells (CTCs) derived from the primary are shed into bloodstream or lymphatic system. These rare (1−10 per mL of blood) warrant a poor prognosis and correlated with shorter overall survival in several cancers (e.g., breast, prostate colorectal). Currently, anti-EpCAM-coated magnetic bead-based CTC capturing system is gold standard test approved by U.S. Food Drug Administration (FDA) for enumerating CTCs bloodstream. This based on use beads coated anti-EpCAM markers, which...
ABSTRACT Background Molecular profiling of circulating tumor DNA (ctDNA) is a helpful tool for cancer treatment indication or the early detection relapse. A subset patients with advanced lung adenocarcinoma cancers (NSCLC)can be cured by immunotherapy, radiotherapy, and/or chemotherapy combined regimens, targeted therapies depending on their ctDNA molecular profile. However, clinical interpretation negative result remains challenging. Cell-free (cfDNA) in association nucleosomes are released...
Circulating tumor cells (CTCs) could be interesting biomarkers to assess the severity of cancer, monitor evolution disease in real-time, and guide therapeutic strategies. However, their study is challenging as they are present an ultra-low concentration blood, at about 1 ppm most. Besides, CTCs share common physical properties with some white blood (WBCs), which limits performances physical-based isolation. On other hand, sorting from biological surface markers does not allow for obtaining...
Abstract The materials present the good practices of Total E&P Qatar to make its crisis management and emergency response effective: way it is organized people involved are behaving. To protect assets, TEPQ has developed own Affiliate Emergency Response Plan. In case response, sets different group structured in cells. Each cell role depending on situation. cross-functionality between each for application plans warranted by a central Cell. Real cases confirmed effectiveness...
Abstract Introduction: NSCLC accounts for about 80-85% of all lung cancers. Approximately 10-50% patients with harbor EGFR activating mutations, such as in-frame deletions in exon 19 (Ex19del). Currently, advanced NSCLC, testing sensitizing mutations is mandatory prior to the administration anti-EGFR inhibitors Osimertinib. The CAM xenograft offers a rich environment nutrients and embryonic growth factors, favorable aggressive tumor development, its highly vascularized membrane natural...
Abstract Introduction: Treatment options of lung cancer (LC) comprise radiotherapy, and/or combined treatment approaches, including chemotherapy, immunotherapy and targeted therapies based on the tumoral molecular profile. Following curative-intent first-line therapies, clinical surveillance involves serial CT imaging. However, such can detect only macroscopic disease recurrence is frequently inconclusive. NGS has been utilized to help identify monitor plans. Nucleosomes, complexes DNA...
Abstract Background: Noninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential to obviate need for some invasive biopsies in cancer patients. We sought validate an ultra-deep Next-Generation Sequencing (NGS) assay patients with Non-Small-Cell Lung Cancers (NSCLC) detecting Minimal Residual Disease (MRD) following curative-intent NSCLC treatment or EGFR detection at early stage. Patients and Methods: carried out targeted NGS Plasma-SeqSensei™ Solid Cancer IVD Kit on cfDNA...
Abstract Background: In patients with advanced lung adenocarcinoma cancers, a subset can be cured by radiotherapy, and/or combined regimens, including chemotherapy, immunotherapy, or targeted therapies based on somatic molecular profiling. Nucleosomes are basic elements of chromatin, composed 147bp DNA wrapped around an octamer histones. Cell-free (cfDNA) and nucleosomes released into the bloodstream upon cell death. addition to genetic alterations, epigenetic modifications found play key...
We report a case of metastatic pancreatic neuroendocrine carcinoma associated with paraneoplastic Cushing's syndrome, successively treated five lines treatment (platin-etoposide, LV5FU2-dacarbazine, FOLFIRINOX, pembrolizumab, and paclitaxel) anti-secretory treatment. Circulating-free DNA (cfDNA) was analysed at each morphological evaluation starting from the second-line cfDNA changes were well correlated disease course, may be used as predictive marker and/or an early response. In addition,...